Towards Healthcare
Injection Flu Shot Market to Grow at 10.93% CAGR till 2034

Injection Flu Shot Market Surges with AI and mRNA Focus

Projections indicate that, the global injection flu shot market will increase from USD 10.63 billion in 2024 to USD 29.97 billion by 2034, experiencing a CAGR of 10.93% over the next 10 years. The increasing number of elderly individuals, who are more susceptible to serve flu complications, has heightened the demand for the flu vaccines. North America led the global market owing to robust healthcare infrastructure in the North America region.

Content

  • Last Updated: 29 October 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and market strategy to her research.

Shivani contributes to Towards Healthcare and plays an active role at Precedence Research, where she focuses on delivering in-depth market intelligence, competitive analysis, and trend forecasting across pharmaceuticals, medical devices, digital health, and healthcare services. Her insights support healthcare companies, investors, and policymakers in making data-backed decisions in a highly regulated and rapidly evolving sector.

Additionally, Shivani collaborates with Statifacts, further expanding her healthcare domain reach by engaging in diverse projects across global markets. Her strength lies in transforming complex clinical and commercial data into strategic narratives that help stakeholders navigate the future of healthcare.

Talk to us
FAQ's

The injection flu shot market is worth USD 11.8 billion in 2025, and by 2034, it is forecasted to hit USD 29.97 billion, registering a CAGR of 10.93% over the decade.

North America is leading the injection flu shot market due to the presence of major key players high vaccination awareness, and robust government immunization programs.

Some key players include Seqirus (CSL), Sanofi Pasteur, GlaxoSmithKline (GSK), Pfizer Inc., Moderna, Inc., Lonza, IDT Biologika Bavarian Nordic, Novartis and Skyepharma among others

All individuals aged 6 months and older are recommended to receive the flu shot. Priority groups include older adults (65+), pregnant women, children, and individuals with chronic health conditions or weakened immunity.

Gavi, the Vaccine Alliance, Food and Drug Administration, American Immunization Registry Association, clinicaltrials.gov, WHO, Association of Immunization Managers, JAMA, Vaccine Access Cooperative, National Industry Associations, GOV.UK
Any Questions